Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature

Journal of Clinical Investigation

Volumn 127, Issue 6, 2017, Pages 2249-2261

  Thanabalasuriar, Ajitha ^a   Surewaard, Bas G J ^a   Willson, Michelle E ^a   Neupane, Arpan S ^a   Stover, Charles K ^b   Warrener, Paul ^b   Wilson, George ^b   Keller, Ashley E ^b   Sellman, Bret R ^b   DiGiandomenico, Antonio ^b   Kubes, Paul ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BISPECIFIC ANTIBODY; CD11B ANTIGEN; COMPLEMENT COMPONENT C3; FC RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PSL EXOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR; TYPE 3 SECRETION INJECTISOME; UNCLASSIFIED DRUG; ANTIGEN V, PSEUDOMONAS; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; BACTERIAL TOXIN; COMPLEMENT; MEDI3902; MONOCLONAL ANTIBODY; PORE FORMING CYTOTOXIC PROTEIN;

ACIDIFICATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; IMMUNE EVASION; IMMUNIZATION; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INTRAVITAL MICROSCOPY; KUPFFER CELL; LUNG BLOOD VESSEL; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PHAGOSOME; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; 129 MOUSE; ANIMAL; C57BL MOUSE; FEMALE; IMMUNOLOGY; LUNG; MALE; METABOLISM; MICROBIOLOGY; MICROVASCULATURE; PRECLINICAL STUDY; VASCULARIZATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACTERIAL LOAD; BACTERIAL PROTEINS; BACTERIAL TOXINS; COMPLEMENT SYSTEM PROTEINS; DRUG EVALUATION, PRECLINICAL; FEMALE; KUPFFER CELLS; LUNG; MALE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICROVESSELS; NEUTROPHILS; PHAGOCYTOSIS; PORE FORMING CYTOTOXIC PROTEINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECEPTORS, FC;

EID: 85020184648     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI89652     Document Type: Article

References (32)

1. Sandiumenge A, Rello J. Ventilator-associated pneumonia caused by ESKAPE organisms: cause, clinical features, and management. Curr Opin Pulm Med. 2012;18(3):187-193.
2. Kang CI, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003;37(6):745-751.
3. Guillamet CV, Vazquez R, Noe J, Micek ST, Kollef MH. A cohort study of bacteremic pneumonia: The importance of antibiotic resistance and appropriate initial therapy? Medicine (Baltimore). 2016;95(35):e4708.
4. Tam VH, et al. Prevalence, resistance mechanisms, and susceptibility of multidrugresistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54(3):1160-1164.
5. Kunz AN, Brook I. Emerging resistant Gramnegative aerobic bacilli in hospital-acquired infections. Chemotherapy. 2010;56(6):492-500.
6. Micek ST, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care. 2015;19:219.
7. Lovewell RR, Patankar YR, Berwin B. Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol. 2014;306(7):L591-L603.
8. Turner KH, Everett J, Trivedi U, Rumbaugh KP, Whiteley M. Requirements for Pseudomonas aeruginosa acute burn and chronic surgical wound infection. PLoS Genet. 2014;10(7):e1004518.
9. Gellatly SL, Hancock RE. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis. 2013;67(3):159-173.
10. Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol. 2009;7(9):654-665.
11. Galle M, Carpentier I, Beyaert R. Structure and function of the Type III secretion system of Pseudomonas aeruginosa. Curr Protein Pept Sci. 2012;13(8):831-842.
12. Vance RE, Rietsch A, Mekalanos JJ. Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo. Infect Immun. 2005;73(3):1706-1713.
13. Duncan MC, Linington RG, Auerbuch V. Chemical inhibitors of the type three secretion system: disarming bacterial pathogens. Antimicrob Agents Chemother. 2012;56(11):5433-5441.
14. Heimer SR, Evans DJ, Stern ME, Barbieri JT, Yahr T, Fleiszig SM. Pseudomonas aeruginosa utilizes the type III secreted toxin ExoS to avoid acidified compartments within epithelial cells. PLoS ONE. 2013;8(9):e73111.
15. Limoli DH, Jones CJ, Wozniak DJ. Bacterial extracellular polysaccharides in biofilm formation and function. Microbiol Spectr. 2015;3(3):MB-0011-2014.
16. Mishra M, et al. Pseudomonas aeruginosa Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement- mediated opsonization. Cell Microbiol. 2012;14(1):95-106.
17. MedImmune LLC. Effort to prevent nosocomial pneumonia caused by Pseudomonas aeruginosa in mechanically ventilated subjects (EVADE). NIH Web site. https://clinicaltrials.gov/ct2/show/ NCT02696902?term=MEDI3902&rank=2. Published February 11, 2016. Accessed March 15, 2017.
18. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol. 2012;12(3):201-213.
19. Zeng Z, Surewaard BG, Wong CH, Geoghegan JA, Jenne CN, Kubes P. CRIg Functions as a macrophage pattern recognition receptor to directly bind and capture blood-borne gram-positive bacteria. Cell Host Microbe. 2016;20(1):99-106.
20. Surewaard BG, et al. Identification and treatment of the Staphylococcus aureus reservoir in vivo. J Exp Med. 2016;213(7):1141-1151.
21. Sawa T, et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med. 1999;5(4):392-398.
22. Schneberger D, Aharonson-Raz K, Singh B. Pulmonary intravascular macrophages and lung health: what are we missing? Am J Physiol Lung Cell Mol Physiol. 2012;302(6):L498-L503.
23. Kreisel D, et al. In vivo two-photon imaging reveals monocyte-dependent neutrophil extravasation during pulmonary inflammation. Proc Natl Acad Sci U S A. 2010;107(42):18073-18078.
24. DiGiandomenico A, et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014;6(262):262ra155.
25. D'Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. Targeting the "cytokine storm" for therapeutic benefit. Clin Vaccine Immunol. 2013;20(3):319-327.
26. Faure K, et al. Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model. J Immune Based Ther Vaccines. 2003;1(1):2.
27. Marion CR, et al. Chitinase 3-like 1 (Chil1) regulates survival and macrophage-mediated interleukin- 1β and tumor necrosis factor alpha during pseudomonas aeruginosa pneumonia. Infect Immun. 2016;84(7):2094-2104.
28. Looney MR, Thornton EE, Sen D, Lamm WJ, Glenny RW, Krummel MF. Stabilized imaging of immune surveillance in the mouse lung. Nat Methods. 2011;8(1):91-96.
29. Schweizer HP. Allelic exchange in Pseudomonas aeruginosa using novel ColE1-type vectors and a family of cassettes containing a portable oriT and the counter-selectable Bacillus subtilis sacB marker. Mol Microbiol. 1992;6(9):1195-1204.
30. Schweizer HD. Small broad-host-range gentamycin resistance gene cassettes for site-specific insertion and deletion mutagenesis. BioTechniques. 1993;15(5):831-834.
31. Hoang TT, Karkhoff-Schweizer RR, Kutchma AJ, Schweizer HP. A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene. 1998;212(1):77-86.
32. Wyckoff TJ, Wozniak DJ. Transcriptional analysis of genes involved in Pseudomonas aeruginosa biofilms. Meth Enzymol. 2001;336:144-151.